NL-OMON44961已完成不适用
CHOICE: CHOosing treatment together In Cancer at the End of life<br> - CHOICE: CHOosing treatment together In Cancer at the End of life
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64(—)
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •1. diagnosed with metastasized or locally irresectable cancer
- •2. not eligible for treatment with curative intent
- •3. median life expectancy of <1 year without systemic treatment, and a median survival benefit of systemic treatment of <6 months. This includes, but is not limited to:
- •a. patients with metastases or locally irresectable tumors of the pancreas, esophageus, stomach, liver, gall bladder, and bladder, and patients with metastatic sarcoma or melanoma
- •b. patients with advanced cancer, irrespective of tumour type, who have experienced progression under first line palliative systemic treatment.
- •4. scheduled for a consultation with a participating medical oncologist in which decisions about the start, (dis)continuation or adjustment of palliative systemic treatment will be made. This includes consultations in which:
- •a. a decision to start, forego or postpone a (new line of) systemic treatment will be made
- •b. current systemic treatment is evaluated after a fixed number of cycles and a decision to (dis)continue and/or adjust systemic treatment will be made;Oncologists
- •Eligible are all medical oncologists (in training) treating the eligible patient population with an appointment of at least 1 year after the start of the trial.
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •1. insufficient mastery of Dutch, i.e., inability to understand the 'Gesprekswijzer' as well as the questionnaires as judged by either the physician or the researcher
- •2. cognitive disabilities or a psychiatric disorder that hinder understanding of the 'Gesprekswijzer' as well as the questionnaires as judged by either the physician or the researcher
- •3. not enough time (<2 days) to make sure the Gesprekswijzer is received before the consultation in which decisions are made
- •4. a primary brain tumor or brain metastasizes which significantly affect cognitive functioning;Oncologists
- •Excluded will be oncologists involved in the design of the content of the interventions.
研究者
相似试验
已完成
不适用
CHOICE: CHOosing treatment together In Cancer at the End of lifeadvanced cancermetastasized or inoperable tumoursNL-OMON22913Academic Medical Center, University of Amsterdam192
招募中
不适用
Collaborative Action for cancer control among Mumbai Police.CTRI/2019/04/018748Tata Trusts
已完成
2 期
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion - Metastatic Breast Cancermetastatic breast cancermammacarcinoma10006291NL-OMON41527niversitair Medisch Centrum Groningen200
进行中(未招募)
不适用
Imaging patients for cancer drug selection - metastatic breast cancerMetastatic Breast CancerEUCTR2013-000551-41-NLniversity Medical Center Groningen
已完成
不适用
utritional therapy for cancer patientCTRI/2021/03/031634Rajiv Gandhi university of Health Sciences Grant in aid for advanced research project100
